Analysts have been eager to weigh in on the Healthcare sector with new ratings on Viridian Therapeutics (VRDN – Research Report), Amryt Pharma (AMYT – Research Report) and Elevation Oncology (ELEV – Research Report).
Viridian Therapeutics (VRDN)
SVB Securities analyst Thomas Smith maintained a Buy rating on Viridian Therapeutics today and set a price target of $45.00. The company’s shares closed last Friday at $27.46, close to its 52-week high of $29.99.
According to TipRanks.com, Smith is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viridian Therapeutics with a $43.00 average price target, implying a 56.1% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $46.00 price target.
See today’s best-performing stocks on TipRanks >>
Amryt Pharma (AMYT)
In a report released today, Mani Foroohar from SVB Securities downgraded Amryt Pharma to Hold, with a price target of $14.50. The company’s shares closed last Friday at $7.00.
According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Amryt Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $16.83.
Elevation Oncology (ELEV)
SVB Securities analyst Andrew Berens maintained a Hold rating on Elevation Oncology today and set a price target of $1.00. The company’s shares closed last Friday at $0.75, close to its 52-week low of $0.72.
According to TipRanks.com, Berens is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Elevation Oncology with a $3.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRDN:
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- ‘The Likelihood of Recession in the Next 6 Months Is Low’: Credit Suisse Suggests 2 Stocks to Buy
- Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
- Viridian Therapeutics announces first patient enrolled in THRIVE Phase 3 trial
